Lannett Announces Positive Results of Facilities Inspection

PHILADELPHIA, Sep 29, 2010 (BUSINESS WIRE) -- Lannett Company, Inc. /quotes/comstock/14*!lci/quotes/nls/lci (LCI 4.54, +0.16, +3.65%) today said that the U.S. Food and Drug Administration (FDA) recently completed inspections of the company's manufacturing facilities in Philadelphia and Cody, Wyoming. The inspections concluded with zero observations at the company's facilities in Philadelphia and a total of two minor 483 observations at Lannett's wholly owned subsidiary Cody Laboratories (Cody), a manufacturer/supplier of pain management pharmaceutical products.

"We are committed to maintaining a high level of quality and integrity in the products we manufacture," Arthur Bedrosian, president and chief executive officer of Lannett. "The positive results of these inspections underscore our companywide commitment to regulatory excellence."

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company's website at